Company intelligence / Profile preview

FerroptoCure

Ownership: Private
Development stage: Preclinical

Overview

FerroptoCure is a clinical-stage biotech developing next-generation anticancer drugs by inducing ferroptosis—an iron-dependent form of cell death. Their approach targets the antioxidative systems that allow cancer cells to evade death, with a particular emphasis on cancers resistant to existing therapies. They also have preclinical efforts for companion animal oncology and potential applications in neurodegenerative diseases and hepatitis/NASH. No published human trial results were found as of June 2025.

Therapeutic areas: OncologyGastroenterologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

FC-002

Preclinical

3 more assets in the full pipeline.

Partnerships

Joint research with leading research institutes is mentioned but no specific partners named.

Beyond the preview

Go deeper on FerroptoCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FerroptoCure.